Druggable targets in pediatric low-grade glioma through multi-modal data and screening
Official title: Multi-modal data integration and functional screening to discover druggable targets in pediatric low-grade glioma
Funded at Children's Hosp of Philadelphia · NIH-11342859 · Data updated 2026-11-12
A pediatric brain tumor study aims to find new drug targets by integrating imaging, genetics, and biology data to tailor treatments for children with low-grade gliomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 12, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $737,908 |
| NIH project number | 1R01CA312142-01 |
| Project ID | NIH-11342859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children diagnosed with pediatric low-grade glioma (pLGG), with tumors that can be profiled using imaging and multi-omics.
✕Less likely to help
Children whose tumors do not fit the risk stratification or lack suitable targets may not benefit from these specific therapies.
What this research studies
This project combines imaging, bioinformatics, and cancer biology to identify molecular events linked to tumor progression in pediatric low-grade glioma (pLGG). It will classify new tumors into risk groups using clinicoradiomic data and then use preclinical drug screening to predict which small molecules might work for each risk group. The team will test promising targets in fly and organoid models to validate potential therapies before any human trials. By linking multi-omic signals to drug responses, the study seeks to enable subtype-specific, preclinical testing of targeted treatments for children. If successful, these findings could guide future clinical trials and personalized care for pLGG patients.
Why it matters
Potential benefit: Potentially faster development of targeted therapies tailored to a child’s tumor subtype, improving outcomes and reducing unnecessary treatments.
How similar studies have gone: Similar multi-omic, model-informed approaches have shown promise in aligning drug responses with tumor subtypes in other cancers, but direct translation to pLGG is still exploratory.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Song, Yuanquan — Children's Hosp of Philadelphia
- Study coordinator: Song, Yuanquan
Related research
Other NIH-funded projects on the same topics.
-
OPTIMUM: Engaging LGG patients in understanding how low-grade brain tumors evolve
A large study plans to involve people with low-grade glioma to map how their tumors change from initial diagnosis to recurrence using patient-friendly data sharing and trial connections.
-
Targeted therapies for pediatric low-grade glioma
A pediatric brain tumor project aims to find better, safer targeted treatments for kids with low-grade gliomas.
-
Understanding how diffuse low-grade gliomas disrupt cortical information processing
This study looks at how a common adult brain tumor changes brain circuits and thinking skills, with the aim of guiding better therapies for cognitive problems.
-
Targeting O-mannosylation in pediatric brain tumors driven by BRAF fusion
A pediatric brain tumor project is exploring whether blocking a specific sugar-modifying process called POMT-mediated O-mannosylation can stop tumor growth in tumors driven by KIAA1549-BRAF fusions.
-
Improving patient participation to track how lower-grade brain tumors change over time
This project works with adults who have lower-grade (WHO II/III) glioma to collect surgical tumor samples, medical records, and feedback so researchers can better understand how their tumors change from diagnosis to recurrence.
-
Targeted treatments for childhood low-grade brain tumors
Seeing if more precise RAF-targeting drugs and drug combinations can improve treatment for children with low-grade gliomas, especially tumors with BRAF changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.